what can i use metformin for

Metformin's only established, guideline-supported indication in this packet is type 2 diabetes mellitus as first-line therapy alongside diet and exercise; the packet also documents widespread off-label and investigational use for PCOS, gestational diabetes, prediabetes, metabolic syndrome, obesity, and various cancers, but these are supported by observational, mechanistic, or early-phase evidence rather than guideline recommendations.

Established indication

• Metformin, used along with diet and exercise, remains the recommended initial pharmacologic intervention for type 2 diabetes mellitus per ADA and EASD guidance.
• It is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus, and was FDA approved as an antidiabetic in 1995.

Off-label and investigational uses reported in the literature

• Metformin is used by millions worldwide to treat various conditions including type 2 diabetes mellitus, prediabetes, gestational diabetes mellitus, polycystic ovarian syndrome, obesity, and cancer.
• It is also commonly used off-label for metabolic syndrome and PCOS, conditions characterized by metabolic disturbance.
• Metformin is used to treat obesity, gestational diabetes, and polycystic ovarian syndrome according to a recent pharmacology review.
• In obese patients without diabetes, metformin's weight loss effects are reported as not inferior to those of a recently approved obesity drug, and antenatal metformin during pregnancy reduces maternal weight gain without affecting neonatal outcomes; the Diabetes Prevention Program found beneficial effects on diabetes prevention and durable weight loss.
• Beyond diabetes, metformin has been reported effective for aging-related conditions including degenerative skeletal diseases, cardiovascular diseases, neurodegenerative diseases, tumors, obesity, and other metabolic abnormalities.
• Metformin is also used in the treatment of obesity, infertility, PCOS, and cancers, and has been studied for anti-neoplastic effects including decreasing breast cancer risk and improving overall survival.
• Metformin has emerged as a promising anticancer drug after epidemiological studies revealed reduced cancer risk in individuals using it for type 2 diabetes, with in vitro and in vivo studies showing suppressed growth of cancer cells including glioma and AML cells; however, a phase 1b trial combining metformin with chloroquine in mutant-IDH solid tumors showed a lack of clinical response.
• A narrative review concludes metformin can be used widely in relation to thyroid, endometrial, breast, pancreas, and lung cancers based on published literature, though further randomized trials are warranted.
• A phase II RCT protocol notes metformin's off-label use for metabolic syndrome and PCOS and describes its investigation for reduction of obesity-associated breast cancer risk.

Safety considerations mentioned in the packet

• Clinical use of metformin is associated with gastro-intestinal discomfort, vitamin B12 deficiency, and risk of lactic acidosis.

Sources

• Nutrients in Energy and One-Carbon Metabolism: Learning from Metformin Users — Nutrients
• The Current and Potential Therapeutic Use of Metformin—The Good Old Drug — Pharmaceuticals
• Anticancer activity of metformin: a systematic review of the literature — Future Science OA
• Drug Interactions of Metformin Involving Drug Transporter Proteins — Advanced Pharmaceutical Bulletin
• Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms — Theranostics
• Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis — Diabetes Therapy
• High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells — Biomolecules
• Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol — BMC Cancer
• Metformin as a Potential Treatment Option for Endometriosis — Cancers
• Troxerutin, a herbal metabolite with antidiabetic and antihypercholesterolemic potential, regulates metabolic gene activity in male diabetic rats — Frontiers in Pharmacology
• Metformin Intervention—A Panacea for Cancer Treatment? — Cancers
• Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations — Cell Reports Medicine

Decision support for clinicians, not medical advice. Answers are grounded in the published literature and every claim cites its source in the interactive view.